<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Expanded trinucleotide repeats cause many <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>These include <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) and <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), which are caused by expanded CAG repeats within an allele of the ataxin-3 (ATXN3) and huntingtin (HTT) genes, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Silencing expression of these genes is a promising therapeutic strategy, but indiscriminate inhibition of both the mutant and <z:mp ids='MP_0002169'>wild-type</z:mp> alleles may lead to toxicity, and allele-specific approaches have required polymorphisms that differ among individuals </plain></SENT>
<SENT sid="3" pm="."><plain>We report that <z:chebi fb="0" ids="48021">peptide nucleic acid</z:chebi> and <z:chebi fb="0" ids="48010">locked nucleic acid</z:chebi> antisense oligomers that target CAG repeats can preferentially inhibit mutant ataxin-3 and HTT protein expression in cultured cells </plain></SENT>
<SENT sid="4" pm="."><plain>Duplex <z:chebi fb="40" ids="33697">RNAs</z:chebi> were less selective than single-stranded oligomers </plain></SENT>
<SENT sid="5" pm="."><plain>The activity of the <z:chebi fb="0" ids="48021">peptide nucleic acids</z:chebi> does not involve inhibition of transcription, and differences in <z:chebi fb="2" ids="33699">mRNA</z:chebi> secondary structure or the number of oligomer binding sites may be important </plain></SENT>
<SENT sid="6" pm="."><plain>Antisense oligomers that discriminate between <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant genes on the basis of repeat length may offer new options for developing treatments for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and related <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">hereditary diseases</z:e> </plain></SENT>
</text></document>